Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-11-29 00:00:00 ET · period of report 2023-11-27 · accession 0000950170-23-066796 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-29 | 2023-11-27 | AMLX | Bedrosian Camille L | Chief Medical Off | A - Grant | $0.00 | +58.3K | 58.3K | New | $0 |
| D | 2023-11-29 | 2023-11-27 | AMLX | Bedrosian Camille L | Chief Medical Off | A - Grant | $0.00 | +162.5K | 162.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-27 | A | A | 58,333 | $0.00 | 58,333 | D | — | — | (F1) The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 annual installments, with the first installment vesting on December 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-11-27 | A | A | 162,500 | $0.00 | 162,500 | D | $12.93 · — to 2033-11-26 | 162,500 Common Stock | (F2) 25% of the shares subject to the option shall vest and become exercisable on December 1, 2024, with the remainder vesting in a series of 36 successive monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. |